These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 18027226)

  • 1. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hierarchical testing of multiple endpoints in group-sequential trials.
    Glimm E; Maurer W; Bretz F
    Stat Med; 2010 Jan; 29(2):219-28. PubMed ID: 19827011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On sample size determination in multi-armed confirmatory adaptive designs.
    Wassmer G
    J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical analysis for two-stage seamless design with different study endpoints.
    Chow SC; Lu Q; Tse SK
    J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
    Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis strategies for adaptive designs with multiple endpoints.
    Chang M; Chow SC
    J Biopharm Stat; 2007; 17(6):1189-200. PubMed ID: 18027225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some controversial multiple testing problems in regulatory applications.
    Hung HM; Wang SJ
    J Biopharm Stat; 2009; 19(1):1-11; discussion 12-41. PubMed ID: 19127460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A group sequential Holm procedure with multiple primary endpoints.
    Ye Y; Li A; Liu L; Yao B
    Stat Med; 2013 Mar; 32(7):1112-24. PubMed ID: 23239078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2011 Jul; 21(4):650-68. PubMed ID: 21516562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gatekeeping testing via adaptive alpha allocation.
    Li JD; Mehrotra DV
    Biom J; 2008 Oct; 50(5):704-15. PubMed ID: 18932133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A consistency-adjusted strategy for accommodating an underpowered primary endpoint.
    Huque MF; Alosh M
    J Biopharm Stat; 2012; 22(1):160-79. PubMed ID: 22204533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partition testing in dose-response studies with multiple endpoints.
    Liu Y; Hsu J; Ruberg S
    Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenge of multiple co-primary endpoints: a new approach.
    Chuang-Stein C; Stryszak P; Dmitrienko A; Offen W
    Stat Med; 2007 Mar; 26(6):1181-92. PubMed ID: 16927251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials.
    Wang SJ; James Hung HM; O'Neill RT
    Biom J; 2010 Dec; 52(6):798-810. PubMed ID: 21154897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.